Cargando…
Nuclear receptors: from molecular mechanisms to therapeutics
Nuclear receptors are classically defined as ligand-activated transcription factors that regulate key functions in reproduction, development, and physiology. Humans have 48 nuclear receptors, which when dysregulated are often linked to diseases. Because most nuclear receptors can be selectively acti...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Portland Press Ltd.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8628184/ https://www.ncbi.nlm.nih.gov/pubmed/34825698 http://dx.doi.org/10.1042/EBC20210020 |
_version_ | 1784606966504488960 |
---|---|
author | Frigo, Daniel E. Bondesson, Maria Williams, Cecilia |
author_facet | Frigo, Daniel E. Bondesson, Maria Williams, Cecilia |
author_sort | Frigo, Daniel E. |
collection | PubMed |
description | Nuclear receptors are classically defined as ligand-activated transcription factors that regulate key functions in reproduction, development, and physiology. Humans have 48 nuclear receptors, which when dysregulated are often linked to diseases. Because most nuclear receptors can be selectively activated or inactivated by small molecules, they are prominent therapeutic targets. The basic understanding of this family of transcription factors was accelerated in the 1980s upon the cloning of the first hormone receptors. During the next 20 years, a deep understanding of hormone signaling was achieved that has translated to numerous clinical applications, such as the development of standard-of-care endocrine therapies for hormonally driven breast and prostate cancers. A 2004 issue of this journal reviewed progress on elucidating the structures of nuclear receptors and their mechanisms of action. In the current issue, we focus on the broad application of new knowledge in this field for therapy across diverse disease states including cancer, cardiovascular disease, various inflammatory diseases, the aging brain, and COVID-19. |
format | Online Article Text |
id | pubmed-8628184 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Portland Press Ltd. |
record_format | MEDLINE/PubMed |
spelling | pubmed-86281842021-12-06 Nuclear receptors: from molecular mechanisms to therapeutics Frigo, Daniel E. Bondesson, Maria Williams, Cecilia Essays Biochem Endocrinology Nuclear receptors are classically defined as ligand-activated transcription factors that regulate key functions in reproduction, development, and physiology. Humans have 48 nuclear receptors, which when dysregulated are often linked to diseases. Because most nuclear receptors can be selectively activated or inactivated by small molecules, they are prominent therapeutic targets. The basic understanding of this family of transcription factors was accelerated in the 1980s upon the cloning of the first hormone receptors. During the next 20 years, a deep understanding of hormone signaling was achieved that has translated to numerous clinical applications, such as the development of standard-of-care endocrine therapies for hormonally driven breast and prostate cancers. A 2004 issue of this journal reviewed progress on elucidating the structures of nuclear receptors and their mechanisms of action. In the current issue, we focus on the broad application of new knowledge in this field for therapy across diverse disease states including cancer, cardiovascular disease, various inflammatory diseases, the aging brain, and COVID-19. Portland Press Ltd. 2021-11 2021-11-26 /pmc/articles/PMC8628184/ /pubmed/34825698 http://dx.doi.org/10.1042/EBC20210020 Text en © 2021 The Author(s). https://creativecommons.org/licenses/by/4.0/This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution License 4.0 (CC BY) (https://creativecommons.org/licenses/by/4.0/) . Open access for this article was enabled by the participation of University of Texas M.D. Anderson Cancer Centre in an all-inclusive Read & Publish pilot with Portland Press and the Biochemical Society under a transformative agreement with EBSCO. |
spellingShingle | Endocrinology Frigo, Daniel E. Bondesson, Maria Williams, Cecilia Nuclear receptors: from molecular mechanisms to therapeutics |
title | Nuclear receptors: from molecular mechanisms to therapeutics |
title_full | Nuclear receptors: from molecular mechanisms to therapeutics |
title_fullStr | Nuclear receptors: from molecular mechanisms to therapeutics |
title_full_unstemmed | Nuclear receptors: from molecular mechanisms to therapeutics |
title_short | Nuclear receptors: from molecular mechanisms to therapeutics |
title_sort | nuclear receptors: from molecular mechanisms to therapeutics |
topic | Endocrinology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8628184/ https://www.ncbi.nlm.nih.gov/pubmed/34825698 http://dx.doi.org/10.1042/EBC20210020 |
work_keys_str_mv | AT frigodaniele nuclearreceptorsfrommolecularmechanismstotherapeutics AT bondessonmaria nuclearreceptorsfrommolecularmechanismstotherapeutics AT williamscecilia nuclearreceptorsfrommolecularmechanismstotherapeutics |